medlogicai.org

Clinical intelligence. Better decisions.

Decision-Making Algorithm in Otorhinolaryngology & Head and Neck Surgery

Congenital Hearing Loss

Newborn screening to aetiological diagnosis — the 1-3-6 pathway

Step 1

Step 1 of 6

EV · HIGH

Universal Newborn Hearing Screening

Screen by 1 month — OAE or AABR, NICU infants get AABR

Every newborn is screened before discharge or by one month of age (the "1" of the JCIH 1-3-6 rule). Screening technology is risk-stratified: well-baby nursery infants can be screened with otoacoustic emissions (OAE) or automated auditory brainstem response (AABR); NICU infants and any baby with a JCIH high-risk factor are screened with AABR, because OAE misses auditory neuropathy spectrum disorder (ANSD) — and ANSD is over-represented in the NICU population.

Scala vestibuli · perilymphScala media · endolymph (K⁺-rich)Scala tympani · perilymphOrgan of Corti — outer + inner hair cells
Three scalae: scala vestibuli (perilymph), scala media (endolymph, K⁺-rich, highlighted), scala tympani (perilymph). The organ of Corti rests on the basilar membrane.
  • OAE — well-baby nursery
  • AABR — NICU and any JCIH risk factor
  • Two-stage screen permitted (OAE → AABR for fails)
  • Document screen result before discharge
  • Refer high-risk infants for periodic surveillance even if screen passes

Key statistics

  • EHDI 1-3-6 rule

    1 mo · 3 mo · 6 mo

    Screen by 1 month · diagnose by 3 months · intervene by 6 months — JCIH benchmark

    PMID 15752533

★ High-yield pearls (chapter-wide)

  • Screen by 1 month, diagnose by 3, intervene by 6 — the JCIH 1-3-6 rule is the binding operational metric.
  • OAE-only screens miss ANSD — high-risk infants must be screened with AABR.
  • A passed newborn screen does not rule out CHL — JCIH risk factors warrant ongoing audiological surveillance to age 5.
  • Always send cCMV PCR (saliva or urine) before 3 weeks of age in any infant with congenital SNHL — the diagnostic window closes at 21 days.
  • Comprehensive genetic testing yields a diagnosis in 40–65% of childhood SNHL — first-line in most modern centres.
  • Profound bilateral congenital SNHL → ECG mandatory at diagnosis (Jervell & Lange-Nielsen syndrome).
  • Preauricular pits + SNHL → renal ultrasound (branchio-oto-renal).
  • Cochlear nerve deficiency on MRI changes the implant plan from CI to ABI — confirm before consenting for CI.
  • Cochlear implantation before 12 months drives the best spoken-language outcomes — JCIH target.
  • EVA progresses with head trauma — counsel against contact sports.
  • Post-meningitic SNHL is a CI emergency — beat the cochlear ossification.
  • Re-offer genetic testing every 3–5 years for previously idiopathic cases — panels keep improving.

Evidence base

5 sources
  1. HIGH

    Joint Committee on Infant Hearing · J Early Hear Detect Interv · 2019JCIHPMID 31633729

    Foundational guideline for universal newborn hearing screening — defines 1-3-6 milestones, two-stage screening pathway, AABR requirement for NICU, and the risk-factor surveillance list. Vol 4(2):1-44.

  2. HIGH

    Smith RJH, Bale JF Jr, White KR · Lancet · 2005Peer reviewPMID 15752533

    Lancet seminar covering universal newborn hearing screening rationale, OAE vs AABR selection, and downstream diagnostic pathway. Vol 365(9462):879-890.

  3. HIGH

    Morton CC & Nance WE · N Engl J Med · 2006Peer reviewPMID 16707752

    Authoritative NEJM review of universal newborn hearing screening programmes, pickup rates, and the genetic-aetiology dominance of the screen-positive population. Vol 354(20):2151-2164.

  4. HIGH

    Lieu JEC et al. · JAMA · 2020Peer reviewPMID 33258894

    VERIFY — Contemporary JAMA narrative review framing the modern paediatric hearing-loss diagnostic and management approach — anchors the up-to-date practice context for Step 1. Vol 324(21):2195-2205.

  5. MOD

    NHS England · 2026NHS NHSP / GOV.UK

    UK national protocol for screen technology selection (AOAE first stage, AABR second stage, AABR-only for NICU), reporting timelines, referral pathways, and cCMV-pathway handling. GOV.UK page last updated 25 Feb 2026.

Step 1

Disclaimer

For educational purposes only. Not for clinical use. This platform is an instructional resource intended to support learning about clinical decision-making and the interpretation of investigations. Clinicians remain completely responsible for the interpretation of findings, the formulation of a differential diagnosis, and any clinical decision. Nothing in this application replaces individualized assessment, hands-on training, expert consultation, or established practice guidelines.

Not for profit effort by

Dr. Prahlada N.B

  • MBBS (JJMMC), MS (PGIMER, Chandigarh)
  • MBA in Hospital & Healthcare Management (BITS, Pilani)
  • Postgraduate Certificate in Technology Leadership and Innovation (MIT, USA)
  • Executive Programme in Strategic Management (IIM, Lucknow)
  • Senior Management Programme in Healthcare Management (IIM, Kozhikode)
  • Advanced Certificate in AI for Digital Health and Imaging Program (IISc, Bengaluru)

Supporting organisations

  • Karnataka ENT Hospital and Research Centre (R)
  • Champions Educational and Medical Society (R)
  • Amogh Foundation